Activation of TNF-α and IL-1β in breast cancer can lead to abnormal genetic transcription, which is beneficial to cancer cells and aids in their resistance to apoptosis, making Nf-κB a critical target in breast cancer therapeutics, particularly in the more aggressive subtypes [114]. The gene discussed is NFKB1; the disease is cancer.